Dr Reddy's completes acquisition of GSK's penicillin facility in US

31 Mar 2011 Evaluate

Dr Reddy's Laboratories has completed the acquisition of GlaxoSmithKline's (GSK) oral penicillin facility and product portfolio in the US. Dr. Reddy's assumes the ownership of the penicillin manufacturing site in Bristol, Tennessee, US, and rights for the Augmentin and Amoxil brands in the United States.

GSK would retain the existing rights for these brands outside the US. The agreement to acquire the facility was signed by Dr Reddy's and GSK in November 2010. As per the company the buy was in line with its strategy to scale up its generics business in North America. It would also bring in an opportunity to explore additional synergy with its other businesses.

In 2009, Dr Reddy's had entered into a strategic partnership with GSK through which GSK gained access to a basket of 100 products of Dr Reddy's branded pharmaceutical segment to be sold in emerging markets.crackcrack

Dr. Reddys Lab Share Price

1342.45 16.45 (1.24%)
20-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.50
Dr. Reddys Lab 1342.45
Cipla 1472.45
Lupin 2147.55
Zydus Lifesciences 973.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.